Why the study?
To explore the synergistic impact of PD-L1 and Akt overexpression in adipose-derived mesenchymal stem cells for ameliorating cardiac dysfunction after MI.
Does intramyocardial transplantation of PD-L1 and Akt overexpressing adipose-derived mesenchymal stem cells improve cardiac function and reduce infarct size compared to unmodified stem cells or no treatment in a rat model of acute myocardial infarction?
Does intramyocardial transplantation of PD-L1 and Akt overexpressing adipose-derived mesenchymal stem cells improve cardiac function and reduce infarct size compared to unmodified stem cells or no treatment in a rat model of acute myocardial infarction?
Genetic engineering of adipose-derived mesenchymal stem cells to overexpress PD-L1 and Akt significantly enhances their resistance to oxidative stress and improves myocardial protection and systolic function in a rat model of acute myocardial infarction via upregulation of CD25+ regulatory T cells.
Answers are grounded in this paper and cite their sources.
Dual PD-L1/Akt AdMSCs remain preclinical after MI; leaves open immunomodulatory stem-cell engineering for ischemic heart disease.
This study explores the synergistic impact of Programmed Death Ligand 1 (PD-L1) and Protein Kinase B (Akt) overexpression in adipose-derived mesenchymal stem cells (AdMSCs) for ameliorating cardiac dysfunction after myocardial infarction (MI). Post-MI adult Wistar rats were allocated into four groups: sham, MI, ADMSC treatment, and ADMSCs overexpressed with PD-L1 and Akt (AdMSC-PDL1-Akt) treatment. MI was induced via left anterior descending coronary artery ligation, followed by intramyocardial AdMSC injections. Over four weeks, cardiac functionality and structural integrity were assessed using pressure–volume analysis, infarct size measurement, and immunohistochemistry. AdMSC-PDL1-Akt exhibited enhanced resistance to reactive oxygen species (ROS) in vitro and ameliorated MI-induced contractile dysfunction in vivo by improving the end-systolic pressure–volume relationship and preload-recruitable stroke work, together with attenuating infarct size. Molecular analyses revealed substantial mitigation in caspase3 and nuclear factor-κB upregulation in MI hearts within the AdMSC-PDL1-Akt group. Mechanistically, AdMSC-PDL1-Akt fostered the differentiation of normal T cells into CD25+ regulatory T cells in vitro, aligning with in vivo upregulation of CD25 in AdMSC-PDL1-Akt-treated rats. Collectively, PD-L1 and Akt overexpression in AdMSCs bolsters resistance to ROS-mediated apoptosis in vitro and enhances myocardial protective efficacy against MI-induced dysfunction, potentially via T-cell modulation, underscoring a promising therapeutic strategy for myocardial ischemic injuries.
No takes yet. Share an insight, caveat, or question.
Lin et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: